BioAsia 2024: Accelerating Startups onto the Global Stage of Innovation

BioAsia 2024: Accelerating Startups onto the Global Stage of Innovation

New Delhi, 20th February 2024: BioAsia 2024, Asia’s largest life-sciences and healthcare conference, is set to ignite innovation and entrepreneurship with its amplified focus on Startup showcase. As Asia’s premier life sciences event, BioAsia, hosted by the State government of Telangana, is poised to transform the entrepreneurial journey for startups within the healthcare and life sciences sectors.

The ‘Innovation Zone’ at BioAsia 2024 will be a dynamic hub showcasing the Startup Stage Pavilion and the Incubator Pavilion, igniting innovation, and unlocking investment opportunities. In line with BioAsia’s ethos of fostering innovation, a select group of about 70 startups have earned coveted spots in the 21st edition of this global conference to showcase their innovative solutions that have potential to transform healthcare globally. These startups will benefit from participation fee waivers and complimentary display booths, providing them with a prestigious platform to present their ground-breaking concepts.

In a unique and unparalleled opportunity, selected startups not only gain access to complimentary exhibition space but also unlock the doors to exclusive interactions with industry titans such as Mr. David Ricks, CEO of Eli Lilly, Mr. Chris Boerner, CEO of Bristol Myers Squibb, and other influential Global Leaders. This golden opportunity, exclusive to BioAsia, offers startups unprecedented access to invaluable mentorship, networking, and potential partnerships with global leaders in the life sciences and healthcare sectors. It’s an unparalleled chance to propel their innovations onto the world stage and accelerate their journey towards success.

The response from industries to attend BioAsia 2024 has been overwhelming, with numerous companies eagerly lining up to participate. The event has attracted interest from both national and international corporations, indicating a strong desire to engage with the latest innovations and developments in the life sciences and healthcare sectors. This enthusiastic response underscores the significance of BioAsia as a premier platform for industry collaboration, networking, and growth, providing start-ups with unparalleled opportunities for exposure, mentorship, and potential partnerships to accelerate their growth trajectory.

The line-up of startups set to grace BioAsia 2024 spans a diverse spectrum, from medical technology startups revolutionizing Drug Discovery Platforms to medical device startups solving for cancer screening, nasal septum, limb movements etc., Additionally, biotechnology startups are making strides in areas such as small molecule nanoparticles and novel drug candidates.

Mr. D Sridhar Babu, Hon’ble Minister for Industries and IT, Government of Telangana said “We are thrilled by the overwhelming response from industries to participate in BioAsia 2024, demonstrating the event’s pivotal role in fostering innovation and collaboration within the life sciences and healthcare sectors. This enthusiasm extends to the start-up ecosystem, where promising ventures eagerly anticipate showcasing their ground-breaking solutions to a global audience. As we witness enthusiastic engagement from both national and international companies, it reaffirms our commitment to positioning Telangana as a global leader in the field, empowering start-ups to thrive and innovate on a world stage.”

Mr. Jayesh Ranjan, IAS, Principal Secretary, I&C and IT, Government of Telangana stated, “As AI continues to permeate the life sciences sector, there is a growing interest among stakeholders to leverage its potential for accelerating research and development in healthcare. To fuel this momentum, Incubator Pavilion and Innovation Zone will be aimed at fostering innovation and business growth through the application of data and AI in healthcare and life sciences.”

Mr. Shakthi Nagappan, Director (Lifesciences), Government of Telangana said “After witnessing the positive impact of these initiatives in previous editions of BioAsia, we are further enhancing this platform. With this year’s theme centered around the Data and AI revolution, BioAsia 2024 presents an unparalleled opportunity to forge partnerships and drive impactful collaborations,” he added.

Start-up Stage has witnessed an overwhelming response from startups worldwide, with over 700 innovative ventures vying for recognition on this prestigious platform. A panel of seasoned experts representing both industries and academia have shortlisted approximately 70 start-ups for exhibiting at the venue. Among these, the top 5 standouts will have the exceptional honor of presenting their groundbreaking ideas during BioAsia’s Valedictory session, further amplifying their visibility and potential for collaboration. BIRAC, Government of India has partnered with BioAsia for the start-up stage further solidifying the event’s stature as a catalyst for fostering innovation and entrepreneurial growth in the life sciences and healthcare sectors.

With the theme “Data & AI: Redefining Possibilities” BioAsia 2024 is set to take place from February 26th to 28th, 2024, in Hyderabad. Over three days, industry stalwarts, distinguished scientists, researchers, and entrepreneurs will converge to explore the potential of reshaping the future of healthcare delivery in the country. Through engaging discussions, BioAsia aims to integrate cross-sectional ecosystems, harness disruptive technologies, and prioritize quality healthcare with accessibility and affordability at the forefront.

Over the years, the event has immensely benefitted from its participant history including the likes of several Nobel Prize winners, Lasker Awardees and eminent industry leaders like Mr. Bill Gates (Chair, Gates Foundation), Mr. Satya Nadella (CEO of Microsoft), Mr. Alex Gorsky (Executive Chairman, Johnson & Johnson), Dr. Vas Narasimhan (CEO, Novartis), Mr. Geoff Martha (Chairman & CEO, Medtronic), besides hosting the Country Ministers and Delegates from Asia, America, Africa, and Europe. Being the first edition post pandemic, BioAsia 2023 was extremely successful with the virtual participation of more than 3000 global participants from over 50+ Countries.